|
|
 |
|
Viewing report
|
|
|
|
Progenics Pharmaceuticals, Inc. (PGNX) - Financial and Strategic SWOT Analysis Review
GlobalData, June 2011, Pages: 39
Progenics Pharmaceuticals, Inc. (PGNX) - Financial and Strategic SWOT Analysis Review
Summary
Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company engaged in development and commercialization of innovative therapeutic products for the treatment of unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company’s is principally into the developing the drugs in the gastroenterology, virology and oncology. Progenics’ principal programs are focused on symptom management and supportive care and the treatment of Human Immunodeficiency Virus (HIV) infection, cancer gastroenterology and virology. The company's first commercial product is RELISTOR and the products under the pipeline are PRO 140, PSMA Antibody Drug Conjugate and PSMA Vaccines. It is operating through a wholly owned subsidiary called PSMA Development Company LLC. Progenics is head quartered in New York, the US.
Progenics Pharmaceuticals, Inc. Key Recent Developments…
May 10, 2011 Progenics Pharmaceuticals Reports Net Loss Of $22.9m For Q1 2011
Mar 15, 2011 Progenics Reports Net Loss Of $18.8m For Q4 2010
Mar 09, 2011 Progenics Pharmaceuticals Names Mark Baker As CEO
Nov 08, 2010 Progenics Reports Net Loss Of $17.1 Million For Q3 2010
Oct 06, 2010 Progenics Receives $4.1 Million NIH Grant To Advance New Clostridium Difficile Antibody Therapy
This comprehensive SWOT profile of Progenics Pharmaceuticals, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Customers who bought this item also bought
Progenics Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011
Progenics Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011
Progenics Pharmaceuticals, Inc.: SWOT Analysis & Company Profile
Progenics Pharmaceuticals, Inc. - Strategy and SWOT Report
Progen Pharmaceuticals Limited (PGL) - Financial and Strategic SWOT Analysis Review
Progenics Pharmaceuticals, Inc. - Strategy, SWOT, and Corporate Finance Report
Progenics Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
Micromet, Inc. (MITI) - Financial and Strategic SWOT Analysis Review
Seattle Genetics, Inc. (SGEN) - Financial and Strategic SWOT Analysis Review
Auxilium Pharmaceuticals, Inc. (AUXL) - Financial and Strategic SWOT Analysis Review
|
|
|
|
